REALVNC
9.6.2022 15:02:03 CEST | Business Wire | Press release
VNC Connect by RealVNC, the remote access service used by hundreds of millions of people worldwide, was audited by Cure53 , the Berlin, Germany-based IT security consultancy who have also audited other industry leading software such as Mozilla VPN, 1Password and Bitwarden. The comprehensive audit, which took 86 person days and included VNC Server and VNC Viewer on Linux, Windows and Mac, VNC Viewer for iOS and Android, the VNC Connect management portal and backend services, found 38 security-relevant discoveries, none of which were critical and only three were deemed high severity, and these were fixed immediately. The report states, in conclusion, that RealVNC places a strong focus on the security posture of all its components.
“As the technologists responsible for bringing remote access to the mass market, we are today setting new standards and expectations for security in the face of the challenges of the modern IT environment. IT buyers of remote access technologies should expect no less than independent and comprehensive third-party validation of vendor claims. This is especially true for remote access software where the stakes are high, and a mistake could be reputationally damaging or even existential. With Cure53’s report, buyers can be confident that choosing RealVNC as their remote access vendor will never be a regret,” said Adam Greenwood-Byrne, CEO of RealVNC.
A white box security audit is significantly more in-depth than the more common black box penetration test (which RealVNC also commissions by an external organization annually), as the auditors have access to all of the source code, binaries and API/protocol documentation. Of the 38 vulnerabilities found across the range of software and services tested, 32 have been properly addressed — with the fixes confirmed by Cure53 — while the other six were flagged as either false-alerts or works-as-intended and evaluated to be of lower risk.
“At RealVNC, we operate from the standpoint that no company should ever take a vendor’s word for it when they claim their software is secure, which is why we chose to complete a white box audit with a highly regarded security consultancy to prove it,” said Andrew Woodhouse, CIO of RealVNC.
The Cure53 team is highly motivated to find issues when completing white box penetration tests. The fact that no critical threats were found reinforces RealVNC’s focus on ensuring its customers remain safe from threats when using VNC Connect.
“Cure53 is happy to state that test preparation, test execution and also the fix verification, which is one of the most important parts of such an audit, went smoothly and professionally. It is clear that RealVNC has demonstrated a genuine interest in ensuring VNC Connect's security and is prepared and committed to maintaining the high standards we have observed,” said Dr.-Ing. Mario Heiderich, Founder of Cure53.
Headquartered in Cambridge, RealVNC's products for desktop, mobile and embedded platforms make it easy for users to access and operate devices remotely while enabling remote users to work with technicians to resolve problems easily.
“We’re not shying away from any of the issues the report found. We actively fixed issues as they came up and, as security is an ever changing landscape, we’ll continue to ensure the security of VNC Connect in future iterations of the service,” said Ben May, Head of Cyber Security at RealVNC.
To review Cure53's summary of the audit, click here , and to learn more about why RealVNC chose to conduct a Cure53 audit, click here .
ABOUT REALVNC
RealVNC’s secure remote access and management software is used by hundreds of millions of people worldwide. Their software helps organizations cut costs and improve the quality of supporting remote devices and applications, as well as enabling remote working. RealVNC is the original, UK-based, inventor of VNC remote access software and they support an unrivaled mix of desktop, mobile and embedded platforms.
ABOUT CURE53
Cure53 offers classic black-box penetration tests (zero-knowledge) as well as white-box tests and code audits. Web application and mobile app developers speak many languages and so do we. From classic languages such as PHP, JavaScript, ActionScript, Java, Ruby, Python and Perl to more exotic candidates like web back-ends written in C++ and Delphi – we've seen them.
Since Cure53 was founded in 2007, we have performed hundreds of penetration tests against all kinds of web applications, online services, hardware interfaces, mobile applications, libraries and crypto tools. We value manual and thorough tests, human interaction and communication and a short yet-to-the-point penetration test report without overhead or pie charts no one wants to see.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220609005211/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Vertex to Present New Data on ALYFTREK® at the North American Cystic Fibrosis Conference9.10.2026 19:15:00 CEST | Press release
- Data on ALYFTREK in children ages 2 to 5 years demonstrate recovery of pancreatic function in some children –- Additional abstracts on clinical and real-world evidence on CFTR modulators also presented - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced new interim data from the ALYFTREK® (vanzacaftor/tezacaftor/deutivacaftor) 2 to 5 years old open-label extension study, highlighting recovery of exocrine pancreatic function in some children in that age group, allowing those children to discontinue pancreatic enzyme replacement therapy (PERT). Pancreatic exocrine insufficiency in children with cystic fibrosis (CF) was previously believed to be irreversible. These data were presented at the North American Cystic Fibrosis Conference (NACFC). “The data presented at NACFC underscore the safety and efficacy of our CF medicines in the real world and in clinical trials in younger age groups. The data from the Phase 3 open-label study in 2 to 5 year olds evaluating exocrine p
Andersen Consulting udvider med TalentSmartEQ for at fremme lederskab og virksomhedstransformation9.10.2026 18:48:00 CEST | Pressemeddelelse
Andersen Consulting styrker sine kompetencer inden for humankapital gennem en samarbejdsaftale med TalentSmartEQ, en San Diego-baseret virksomhed, der har fokus på at skabe praktiske, engagerende og handlingsorienterede læringsoplevelser med udgangspunkt i emotionel intelligens (EQ) og lederudvikling. I mere end to årtier har TalentSmartEQ arbejdet sammen med organisationer verden over med henblik på at udvikle ledelseskompetencer ved hjælp af emotionel intelligens og dermed styrke medarbejderengagement, teamwork og de samlede resultater. Virksomheden kombinerer forskningsbaserede metoder med praktiske læringsforløb, vurderinger, coaching og skræddersyede programmer, der skal omsætte opbygningen af emotionel intelligens til vedvarende ændringer i adfærden på arbejdspladsen. Som førende aktør i branchen samarbejder TalentSmartEQ med organisationer lige fra Fortune 500-virksomheder til offentlige myndigheder og privatejede virksomheder. "Organisationer stiller stadig større krav til dere
Verdant Rock Receives A (low) Financial Strength Rating from Morningstar DBRS, Adding a Second International Investment-Grade Assessment9.10.2026 16:00:00 CEST | Press release
Verdant Rock now holds Financial Strength Ratings from both Fitch Ratings and Morningstar DBRS, providing counterparties with dual-agency confirmation and reinforcing the security architecture behind each financial guarantee Verdant Rock Limited, a Bermuda Monetary Authority-regulated Class 3B insurance company, has received an A (low) Financial Strength Rating from Morningstar DBRS. The rating reflects Verdant Rock’s financial strength and its capacity to meet policyholder obligations as an investment-grade financial guarantor for Emerging Markets credit. Morningstar DBRS is a global credit rating agency with coverage across North America, Europe, Asia, and Latin America. Its assessment of Verdant Rock reflects the company’s strong projected earnings ability, robust risk profile, sound liquidity, and good capitalization. Morningstar DBRS also assigned an A (low) Issuer Rating to Verdant Rock. The rating follows Verdant Rock’s BBB+ Long-Term Insurer Financial Strength Rating with a Sta
Tecnotree Named a Visionary in the Inaugural 2026 Gartner® Magic Quadrant™ for CSP AI-Enabled Marketing and Sales Solutions9.10.2026 15:17:00 CEST | Press release
We think Gartner recognizes Tecnotree's open, governed approach to agentic AI as operators make AI the engine of their revenue operations Tecnotree, a global digital platform and services leader for AI, 5G, and cloud-native technologies, today announced that Gartner has positioned it as a Visionary in the first-ever Magic Quadrant for AI-Enabled CSP Marketing and Sales Solutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261009905430/en/ Tecnotree Named a Visionary in the Inaugural 2026 Gartner® Magic Quadrant™ for CSP AI-Enabled Marketing and Sales Solutions A new category for a new operating model. CSPs are fighting saturated markets, rising acquisition costs, and accelerating churn. They are responding with AI-driven automation across the full revenue cycle, from segmentation and campaigns to lead management, CPQ, and renewals, increasingly executed by autonomous agents. According to us, Gartner creation of this Magi
Positive New Data on Corcym’s Perceval Plus Sutureless Aortic Heart Valve Encompasses up to 7-Year Follow-up9.10.2026 15:15:00 CEST | Press release
Data Presented at Annual Meeting of European Association for Cardio-Thoracic Surgery (EACTS), Along with 6 Perceval Plus E-PostersEACTS Also Marks Commercial Launch of TriMemo and Memo 4D Curve, Innovative Repair Devices for Tricuspid and Mitral Valves Corcym, a global medical device company dedicated to cardiac surgery, today announced that positive mid-term data from a sub-analysis of its Perceval Plus sutureless aortic heart valve as part of its MANTRA clinical trial was featured in an oral presentation today at the annual meeting of the European Association for Cardio-Thoracic Surgery (EACTS). The study is the longest follow-up available for Perceval Plus and the FREE tissue treatment from an international multicenter study, and demonstrated excellent durability, safety and quality of life improvements. Perceval Plus is the only sutureless and collapsible aortic surgical heart valve. Its unique design performs in any surgical scenario and is optimal for endoscopy and robotics. The
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
